FLASHBACK – Gennifer Flowers: Hillary Clinton an
FLASHBACK – Gennifer Flowers: Hillary Clinton an ‘Enabler’ Who Encouraged Bill to ‘Do Whatever He Does With Women’
NEW YORK — In a news making interview with me last October, Gennifer Flowers, who says she was Bill Clinton’s mistress for 12-plus years, slammed Hillary Clinton as an “enabler” who has “encouraged” her husband “to go out and do whatever he does with women.”
Flowers found herself back in the headlines Saturday when Donald Trump threatened on Twitter to bring her to the first presidential debate after Trump troll Mark Cuban said he’d sit in the front-row. Flowers responded promptly on social media, writing, “Hi Donald Trump… I’m in your corner. Of course I will see u at the debate !!”
Besides Monical Lewinsky, Flowers has the distinction of being the only other woman with whom Bill Clinton has admitted to having had a sexual encounter outside of his marriage.
In a wide-ranging interview last October on my Sunday night talk radio show “Aaron Klein Investigative Radio,” Flowers slammed Hillary’s attempt to frame her campaign in part around women’s issues as “a joke.”
“Woman’s rights. Ha!” Flowers stated. “I personally have worked my tail off to get where I am in the entertainment business, which has not been easy since the Clinton scandal, by the way. … Hillary never put up a shingle and worked for her clients and built her clientele. She always got things on the back of her husband. … I think it’s a joke that she would run on women’s issues.”
She continued: “You know, people criticize me for talking about her because I had an affair with her husband.”
“And I don’t blame them for that. I understand that. I understand that they can be mad at me. I get it. I accept my responsibility. … But she’s never accepted her responsibility at being an enabler. She’s been an enabler that has encouraged him to go out and do whatever he does with women.”
Ominously, Flowers said at the time she believes it is a legitimate campaign issue to bring up Bill Clinton’s past treatment of women.
“Monica and I are the only two women that Bill has admitted to. I don’t know the other ladies personally. Perhaps their stories are legitimate. I don’t know that.”
“But just because we are women doesn’t make our stories less important. Our stories should come back up with the circumstances, with Hillary running. It should come back to the forefront again.”
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP
Scroll down for more posts ▼
Top 10 Most Recent News Articles
The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...
Continue Reading
GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...
Continue Reading
Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...
Continue Reading
The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...
Continue Reading
Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...
Continue Reading
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....
Continue Reading
Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...
Continue Reading
Top 5 Most Recently Viewed Articles
Coke Florida's Volunteer Contributions for Coastal Cleanup Day Coca-Cola Beverages Florida, LLC (Coke Florida) was excited to take part in the worldwide celebration of International Coastal Cleanup (ICC) Day. This initiative, which focuses on sustainability and building community resilience, encouraged employees across the company's vast market to unite for a meaningful...
Continue Reading
LifeMD Maintains Buy Rating Amid Positive Developments BTIG has reaffirmed its support for LifeMD Inc (NASDAQ: LFMD) by maintaining a Buy rating and a price target of $12.00 for the company’s stock. This endorsement comes at a pivotal time as the company experiences recent developments in the ongoing legal proceedings regarding tirzepatide, a drug used for treating type...
Continue Reading
Innovative Heating Pad Adapter for Vehicles Inventors continuously strive to enhance daily experiences, and one such innovation is set to revolutionize comfort during travel. An inventor, inspired by the need for warmth while driving, developed the RIDE ALONG PRONG PLUG IN, a unique electric heating pad adapter accessible through a vehicle's cigarette lighter socket....
Continue Reading
Hang Feng Capital Excels at Hong Kong FinTech Week Recently, a remarkable event unfolded in the heart of Asia's financial landscape as Hang Feng Capital showcased its innovations during Hong Kong FinTech Week. Co-hosted by the local government and InvestHK, this pivotal event brought together over 700 exhibitors, 800 speakers, and an impressive crowd of 37,000 attendees...
Continue Reading
Autoliv Inc. got slapped with a serious reality check back in 2024 when JPMorgan revised its price target to $119, up just a hair from $117. You could feel the desks twitching as analysts dove into the automotive safety systems market, flagging Autoliv’s shaky standing amidst some forecasted storms brewing on the horizon. Global light vehicle production was supposed to...
Continue Reading